Featured Image

Manufacturing Productivity  in Q4 came in light of estimates this morning: 1.3% reported versus 1.6% anticipated. However, in a measure of good news, the  Trade Deficit  (delayed til now due to the government shutdown) was down to $49.31 billion from the $54.3 billion expected.

In Q4 earnings news, Zacks Rank #2 (Buy)-rated  General Motors  GM  outperformed expectations on both top and bottom lines: $1.43 per share versus $1.21 expected and $38.4 billion over $37 billion in the Zacks consensus, respectively. Earnings were down year over year by 13%, but sales in the quarter were 1.8% higher than in the year-ago quarter.

Big Pharma major  GlaxoSmithKline  GSK  also topped estimates for both earnings and revenues in its Q4 report, with 80 cents per share beating by a dime on $10.54 billion against expectations of $9.85 billion. EPS is now expected to decline for full-year 2019, although Vaccines were up 18% in the quarter.

Healthcare giant  Humana  HUM  also brought positive surprises to its Q4 results, with $2.65 per share outpacing the $2.53 expected on $14.17 billion improving 1.76% from estimates. Shares were up slightly in the pre-market following the quarterly release.

Take Two Interactive  TTWO easily surpassed fiscal Q3 expectations with $4.05 per share well ahead of the $2.75 expected, whereas revenues $1.57 billion in sales (on video games such as Grand Theft Auto) beat estimates by 5.6%. Yet weaker-than-anticipated guidance - especially after such a big beat - have sent shares of the (formerly?) Zacks Rank #1 (Strong Buy)-rated company down 13% in early trading Wednesday.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

General Motors Company (GM): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

Take-Two Interactive Software, Inc. (TTWO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.

Related Articles